IET

A realization of this project will result in creation of the innovative anticancer “pro-pharmaceuticals” characterized by high effectivity and selectivity with accompanying minimalized side effects of the foreseen therapy. Research will be focused on designing, obtaining and in vitro validation of recombinant proteins called immunoendotoxins able to selectively binding, internalization and cancerous cells killing. The most important element of each immunoendotoxin will be an effector domain of a human origin thus minimalizing possible immunogenicity of the proteins. Low immunogenicity in association with known benefits of immunotoxins-based strategies will result in very potent anticancer therapeuticals.